Intellia Therapeutics Inc... (NTLA)
Intellia Therapeutics Statistics
Share Statistics
Intellia Therapeutics has 103.52M shares outstanding. The number of shares has increased by 7.3% in one year.
| Shares Outstanding | 103.52M |
| Shares Change (YoY) | 7.3% |
| Shares Change (QoQ) | 1.64% |
| Owned by Institutions (%) | 98.29% |
| Shares Floating | 97.42M |
| Failed to Deliver (FTD) Shares | 7.91K |
| FTD / Avg. Volume | 0.23% |
Short Selling Information
The latest short interest is 26.94M, so 26.02% of the outstanding shares have been sold short.
| Short Interest | 26.94M |
| Short % of Shares Out | 26.02% |
| Short % of Float | 29.57% |
| Short Ratio (days to cover) | 7.78 |
Valuation Ratios
The PE ratio is -2.22 and the forward PE ratio is -1.64. Intellia Therapeutics's PEG ratio is 0.71.
| PE Ratio | -2.22 |
| Forward PE | -1.64 |
| PS Ratio | 19.91 |
| Forward PS | 0.3 |
| PB Ratio | 1.32 |
| P/FCF Ratio | -2.82 |
| PEG Ratio | 0.71 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Intellia Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.77, with a Debt / Equity ratio of 0.24.
| Current Ratio | 5.77 |
| Quick Ratio | 5.77 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | -0.4 |
| Debt / FCF | -0.52 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $143.62K |
| Profits Per Employee | $-1.29M |
| Employee Count | 403 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -63.72% in the last 52 weeks. The beta is 2.23, so Intellia Therapeutics's price volatility has been higher than the market average.
| Beta | 2.23 |
| 52-Week Price Change | -63.72% |
| 50-Day Moving Average | 8.99 |
| 200-Day Moving Average | 15.67 |
| Relative Strength Index (RSI) | 50.47 |
| Average Volume (20 Days) | 3.42M |
Income Statement
In the last 12 months, Intellia Therapeutics had revenue of 57.88M and earned -519.02M in profits. Earnings per share was -5.25.
| Revenue | 57.88M |
| Gross Profit | 57.88M |
| Operating Income | -534.26M |
| Net Income | -519.02M |
| EBITDA | -523.98M |
| EBIT | -534.26M |
| Earnings Per Share (EPS) | -5.25 |
Balance Sheet
The company has 189.18M in cash and 210.2M in debt, giving a net cash position of -21.02M.
| Cash & Cash Equivalents | 189.18M |
| Total Debt | 210.2M |
| Net Cash | -21.02M |
| Retained Earnings | -2.18B |
| Total Assets | 1.19B |
| Working Capital | 529.01M |
Cash Flow
In the last 12 months, operating cash flow was -394.09M and capital expenditures -13.98M, giving a free cash flow of -408.07M.
| Operating Cash Flow | -394.09M |
| Capital Expenditures | -13.98M |
| Free Cash Flow | -408.07M |
| FCF Per Share | -4.13 |
Margins
Gross margin is 100%, with operating and profit margins of -923.1% and -896.77%.
| Gross Margin | 100% |
| Operating Margin | -923.1% |
| Pretax Margin | -896.77% |
| Profit Margin | -896.77% |
| EBITDA Margin | -905.33% |
| EBIT Margin | -923.1% |
| FCF Margin | -705.07% |
Dividends & Yields
NTLA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for NTLA is $40, which is 405.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $40 |
| Price Target Difference | 405.1% |
| Analyst Consensus | Buy |
| Analyst Count | 19 |
Scores
| Altman Z-Score | -2.05 |
| Piotroski F-Score | 2 |